Phase II Open Label Non-Randomized Single Agent Study of the SMAC (Second Mitochondrial-Derived Activator of Caspases)-Mimetic Birinapant (TL32711; NSC 756502) in Relapsed Platinum Resistant or Refractory Epithelial Ovarian Cancer, Primary Peritoneal
Phase of Trial: Phase II
Latest Information Update: 20 Apr 2017
At a glance
- Drugs Birinapant (Primary)
- Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Therapeutic Use
- 21 Mar 2017 Status changed from completed to discontinued.
- 13 Nov 2015 Results published in the Cancer
- 24 Apr 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.